Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2016)

Historic Preferred Stock Liabilities for Intellia Therapeutics (NTLA) over the last 2 years, with Q1 2016 value amounting to $88.6 million.

  • Intellia Therapeutics' Preferred Stock Liabilities changed N/A to $88.6 million in Q1 2016 from the same period last year, while for Mar 2016 it was $88.6 million, marking a year-over-year change of. This contributed to the annual value of $88.6 million for FY2015, which is N/A changed from last year.
  • Latest data reveals that Intellia Therapeutics reported Preferred Stock Liabilities of $88.6 million as of Q1 2016.
  • In the past 5 years, Intellia Therapeutics' Preferred Stock Liabilities registered a high of $88.6 million during Q1 2016, and its lowest value of $88.6 million during Q4 2015.